Login to Your Account



Propanc banking on proenzymes aimed at cancer stem cells

By Tamra Sami
Staff Writer

Monday, October 9, 2017

PERTH, Australia – Australian biotech Propanc Biopharma Inc. is advancing its lead product, PRP, toward the clinic in ovarian and pancreatic cancers.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription